Histamine and Bradykinin Pharmacology

Gastric parietal cells receive stimulatory input from three sources: histamine (acting at H2 receptors, Gs-coupled), gastrin (acting at cholecystokinin-2 receptors on the parietal cell and on enterochromaffin-like cells), and acetylcholine (acting at muscarinic M3 receptors, from vagal efferents). All three pathways converge on activation of the hydrogen-potassium ATPase — the proton pump — on the apical membrane of the parietal cell, which pumps hydrogen ions into the gastric lumen in exchange for potassium ions.

Histamine occupies a central amplifying role in this system. Gastrin and acetylcholine both stimulate enterochromaffin-like cells in the adjacent gastric mucosa to release histamine in a paracrine fashion, which then acts on parietal cell H2 receptors. H2 receptor activation raises cyclic adenosine monophosphate via Gs, activating protein kinase A, which activates the proton pump. Because histamine amplifies the response to the other two stimuli as well as acting directly, H2 receptor blockade reduces acid output driven by all three pathways — not just histamine-driven secretion alone.

Cimetidine was the first H2 blocker introduced and remains important as a teaching example of drug interactions through enzyme inhibition. It inhibits multiple cytochrome P450 enzymes through binding at the heme iron via its imidazole ring — a broad inhibitory profile that elevates plasma concentrations of co-administered drugs metabolized by these enzymes. The three drug interactions tested most consistently on Step 1 involve warfarin (increased anticoagulant effect and bleeding risk), phenytoin (elevated levels and toxicity), and theophylline (elevated levels — narrow therapeutic index, risk of arrhythmia and seizures). Any patient on these agents who is started on cimetidine requires monitoring and likely dose reduction of the affected drug.

Cimetidine also binds androgen receptors and acts as an androgen antagonist. In men at therapeutic doses this produces gynecomastia (breast tissue enlargement) and impotence, both reversible on discontinuation. This is a direct receptor-level effect, not a consequence of drug interactions. The correct response to cimetidine-induced gynecomastia is to switch to famotidine. Famotidine has no cytochrome P450 inhibitory activity and no antiandrogenic effects.

Famotidine is the most potent H2 blocker currently in clinical use. It lacks the cytochrome P450 inhibitory and antiandrogenic properties of cimetidine and is the preferred H2 blocker for patients on polypharmacy. It is primarily renally eliminated, and dose reduction is required in significant renal impairment.

Ranitidine was withdrawn from the United States market in 2020 following the discovery of N-nitrosodimethylamine contamination — a probable human carcinogen generated during storage degradation. It should not be taught as an active clinical agent; if encountered in a question, the withdrawal and its reason are the testable facts.

Nizatidine has a pharmacological profile similar to famotidine — no cytochrome P450 inhibition, no antiandrogenic effects, intermediate potency. It is lower yield than cimetidine or famotidine at the Step 1 level.

H2 blockers accelerate healing of duodenal and gastric ulcers by reducing acid exposure. Proton pump inhibitors produce faster healing and are the standard of care for peptic ulcer disease. When peptic ulcer disease is caused by Helicobacter pylori infection — which accounts for most duodenal ulcers — eradication therapy (a proton pump inhibitor plus two antibiotics) is definitive treatment; H2 blockers are not part of standard eradication regimens. H2 blockers remain appropriate for mild uncomplicated disease and maintenance therapy.

H2 blockers are appropriate for mild to moderate gastroesophageal reflux disease without esophageal erosions, where they relieve heartburn and regurgitation. For erosive esophagitis — visible mucosal damage on endoscopy — proton pump inhibitors are required for healing. Proton pump inhibitors provide more complete and sustained acid suppression, which is necessary for mucosal repair; H2 blockers are inadequate as primary therapy for erosive disease.

Cimetidine inhibits multiple cytochrome P450 enzymes, reducing hepatic metabolism of co-administered drugs and raising their plasma concentrations. The three interactions of highest Step 1 relevance are with warfarin (elevated international normalized ratio, bleeding risk), phenytoin (elevated levels, nystagmus and ataxia at toxic concentrations), and theophylline (elevated levels — theophylline has a narrow therapeutic index, with toxicity producing nausea, arrhythmias, and seizures). Famotidine and nizatidine do not inhibit cytochrome P450 to a clinically significant degree. When a clinical vignette presents a patient on warfarin, phenytoin, or theophylline who develops toxicity after starting an H2 blocker, cimetidine is the answer.

Cimetidine binds androgen receptors and acts as an androgen antagonist independent of its acid-suppressing activity. In men at standard therapeutic doses this causes gynecomastia and impotence, both reversible on discontinuation. A Step 1 vignette presenting a man on long-term cimetidine for peptic ulcer disease who develops breast enlargement is a classic scenario; the answer is to switch to famotidine, which has no affinity for androgen receptors.

All H2 blockers are generally well tolerated. Minor adverse effects include headache, dizziness, and mild gastrointestinal symptoms. All are renally excreted and require dose reduction in patients with significant renal impairment to prevent accumulation.

In anaphylaxis, histamine contributes to cardiovascular collapse through both H1-mediated vasodilation and H2-mediated tachycardia and vasodilation in certain vascular beds. This dual receptor contribution is the pharmacological rationale for using combined H1 plus H2 blockade as adjunctive therapy after epinephrine — the combination provides broader histamine receptor coverage than H1 blockade alone and reduces the cutaneous manifestations of anaphylaxis more effectively. Diphenhydramine (H1 blocker) plus famotidine (H2 blocker) is a standard adjunct combination used in clinical practice.

The hierarchy must be clear: epinephrine remains the only first-line treatment. H1 and H2 antihistamines are adjuncts for cutaneous symptoms and do not reverse hemodynamic collapse or bronchospasm. Systemic corticosteroids are also given as adjuncts to suppress the late-phase inflammatory response, though their onset is delayed by several hours and they provide no benefit in the acute emergency. In patients taking beta-blockers who have refractory bronchospasm unresponsive to epinephrine, glucagon is used because it activates adenylyl cyclase via a receptor independent of the beta-adrenergic receptor.